Dedifferentiated chordoma: Clinicopathologic and molecular characteristics with integrative analysis

Yin P. Hung, Julio A. Diaz-Perez, Gregory M. Cote, Johan Wejde, Joseph H. Schwab, Valentina Nardi, Ivan A. Chebib, Vikram Deshpande, Martin K. Selig, Miriam A. Bredella, Andrew E. Rosenberg, G. Petur Nielsen

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Dedifferentiated chordoma is a rare chordoma subtype characterized by a high-grade sarcoma juxtaposed to conventional chordoma. We identified a series of dedifferentiated chordomas, reviewed clinicopathologic features, performed next-generation sequencing in select cases, and analyzed all related English-language publications. Our series included 7 men and 3 women (age 15 to 80 y [median: 54 y]; <1% of >1000 chordomas surveyed). The tumor (2.8 to 24.5 cm [median: 5.8 cm] in size) presented de novo or as recurrence (including postradiotherapy) in sacrum (n=5), skull base (n=2), lumbar spine (n=1), thoracic/mediastinum (n=1), and lung (n=1; as metastasis). Histologically, the dedifferentiated component (3% to 95% [median: 60%]) was pleomorphic-to-fibrosarcomatous, juxtaposed to conventional (n=8) or chondroid (n=2) component. By immunohistochemistry, the conventional/chondroid component consistently expressed cytokeratin and brachyury, whereas the dedifferentiated component showed loss of both. We identified a sacral conventional chordoma with INI1 loss, with one of the lung metastases showing biphasic histology with loss of cytokeratin and brachyury in the dedifferentiated component. Sequencing identified tumor suppressor mutations in 4 tumors, including TP53 mutations in the dedifferentiated component in 3 tumors. Of 7 patients with follow-up, 6 developed metastases; 4 died at 15 to 99 months (median: 24 mo) after dedifferentiated chordoma diagnosis. Collectively, of 87 dedifferentiated chordoma patients described in 1913-2020 (including 10 herein), the median overall survival was 20 months. In summary, dedifferentiated chordoma involves diverse sites and presents de novo, postradiotherapy, or as recurrence/metastasis months-to-years after initial diagnosis. The dedifferentiated component shows loss of brachyury and cytokeratin staining and harbors recurrent TP53 mutations, implicating tumor suppressor dysregulation in chordoma dedifferentiation.

Original languageEnglish (US)
Pages (from-to)1213-1223
Number of pages11
JournalAmerican Journal of Surgical Pathology
Issue number9
StatePublished - Sep 1 2020


  • Brachyury
  • Chordoma
  • Dedifferentiated chordoma
  • Dedifferentiation
  • INI1
  • p53

ASJC Scopus subject areas

  • Anatomy
  • Surgery
  • Pathology and Forensic Medicine


Dive into the research topics of 'Dedifferentiated chordoma: Clinicopathologic and molecular characteristics with integrative analysis'. Together they form a unique fingerprint.

Cite this